WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the first quarter of 2011 in a press release to be issued on Thursday, May 5, 2011 at 7:00 a.m. eastern time. The Company will host a conference call at 9:00 a.m. eastern time that day to discuss these results.
|
Conference Call and Webcast |
|||||||||||||
| Date: | Thursday, May 5, 2011 | ||||||||||||
| Time: | 9:00 a.m., Eastern Time | ||||||||||||
|
|
|||||||||||||
|
Conference Call Numbers |
|||||||||||||
| Domestic (toll free): | (877) 868-1831 | ||||||||||||
| International: | (914) 495-8595 | ||||||||||||
| Webcast: | |||||||||||||
A replay of the conference call will be available for seven days following the call and can be accessed by dialing toll-free (800) 642-1687 and outside the U.S. (706) 645-9291. The confirmation code for replayed calls is 62154751.
About ArQule
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an inhibitor of the c-Met receptor tyrosine kinase. The Company has also initiated Phase 1 clinical testing with ARQ 621, designed to inhibit the Eg5 kinesin motor protein, and with ARQ 736, designed to inhibit the RAF kinases. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate) for binding to the kinase.